Spironolactone: Difference between revisions
m added IUPAC-name |
Replaced chemical formula with new style using AWB |
||
| Line 8: | Line 8: | ||
| PubChem = 5833 |
| PubChem = 5833 |
||
| DrugBank = APRD01234 |
| DrugBank = APRD01234 |
||
| C=24 | H=32 | O=4 | S=1 |
|||
| chemical_formula = C<sub>24</sub>H<sub>32</sub>O<sub>4</sub>S |
|||
| molecular_weight = 416.574 g/mol |
| molecular_weight = 416.574 g/mol |
||
| bioavailability = |
| bioavailability = |
||
| Line 18: | Line 18: | ||
| routes_of_administration = PO only |
| routes_of_administration = PO only |
||
}} |
}} |
||
'''Spironolactone''' (marketed as '''Aldactone''' |
'''Spironolactone''' (marketed as '''Aldactone'''®, '''Novo-Spiroton'''®, '''Spiractin'''®, '''Spirotone'''®, or '''Berlactone'''®) is a synthetic 17-[[lactone]] [[steroid]] which is a renal competitive [[aldosterone]] antagonist in a class of [[pharmaceutical]]s called [[potassium]]-sparing [[diuretic]]s, used primarily to treat [[ascites]] in patients with liver disease, low-[[renin]] [[hypertension]], [[hypokalemia]], and [[Conn's syndrome]]. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-[[androgen]] effect, it can also be used to treat [[hirsutism]], and is a common component in [[Hormone replacement therapy (trans)|hormone therapy]] for male-to-female [[transgender]]ed people. It is also used for treating hair loss and acne in women. |
||
==Mechanism of action== |
==Mechanism of action== |
||
Revision as of 23:53, 24 February 2007
| File:Spironolactone.png | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | PO only |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 10 minutes |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.122 |
| Chemical and physical data | |
| Formula | C24H32O4S |
| Molar mass | 416.574 g/mol g·mol−1 |
Spironolactone (marketed as Aldactone®, Novo-Spiroton®, Spiractin®, Spirotone®, or Berlactone®) is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics, used primarily to treat ascites in patients with liver disease, low-renin hypertension, hypokalemia, and Conn's syndrome. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. It is also used for treating hair loss and acne in women.
Mechanism of action
Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone has anti-androgen activity by binding to the androgen receptor and thus preventing it to interact with dihydrotestosterone.[2]
Pharmacokinetics
Spironolactone is fairly rapidly absorbed from the gastrointestinal tract. It is also rapidly metabolised and bound in plasma proteins. Many of its metabolites are also active and one of them, canrenone as potassium canrenoate, is used parenterally when rapid effect is needed. Spironolactone's half-life is only 10 minutes, but canrenone's half-life is 10 to 35 hours, depending on the dose. The main elimination route is in the urine and some also in the bile.
Mortality and morbidity benefit in severe CHF
Spironolactone was shown to have a significant mortality and morbidity benefit in the Randomized Aldactone Evaluation Study (RALES), which studied people with severe congestive heart failure (New York Heart Association functional class III or IV).[3] Patients in the study arm of the trial (those receiving spironolactone) had a relative risk of death (when compared to the placebo group) equal to 0.70 or a 30% relative risk reduction. Patients in the study arm also had significantly less symptoms of CHF and were hospitalized less frequently.
Adverse effects and interactions
Spironolactone is associated with an increased risk of bleeding from the stomach and duodenum, but a causal relationship between the two has not been established.[4] Since it also affects steroid receptors elsewhere in the body, it can cause gynecomastia, menstrual irregularities and testicular atrophy. Other side effects include ataxia, impotence, drowsiness and rashes. A carcinogenic effect has been demonstrated in rats. [2]
People using this drug should avoid salt substitutes.[5]
See also
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Antiandrogen effect [1]
- ^ Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999). "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators". N Engl J Med. 341 (10): 709–17. PMID 10471456.
{{cite journal}}: CS1 maint: multiple names: authors list (link) Free Full Text. - ^ Verhamme KMC, Mosis G, Dieleman JP; et al. (2006). "Spironolactone and risk of upper gastrointestinal events: population based case-control study". Brit Med J. 333 (7563): 330–3. doi:10.1136/bmj.38883.479549.2F.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ LoSalt Advisory Statement (PDF)